BR102021009475B1 - Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico - Google Patents
Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico Download PDFInfo
- Publication number
- BR102021009475B1 BR102021009475B1 BR102021009475-3A BR102021009475A BR102021009475B1 BR 102021009475 B1 BR102021009475 B1 BR 102021009475B1 BR 102021009475 A BR102021009475 A BR 102021009475A BR 102021009475 B1 BR102021009475 B1 BR 102021009475B1
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- peptides
- cov
- sars
- sample
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 165
- 238000000034 method Methods 0.000 title claims abstract description 88
- 238000004445 quantitative analysis Methods 0.000 title claims abstract description 18
- 238000004451 qualitative analysis Methods 0.000 title claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 83
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 54
- 230000003612 virological effect Effects 0.000 claims abstract description 35
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 238000000575 proteomic method Methods 0.000 claims abstract description 6
- 239000000523 sample Substances 0.000 claims description 55
- 238000001514 detection method Methods 0.000 claims description 43
- 150000002500 ions Chemical class 0.000 claims description 24
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 21
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 14
- 238000001819 mass spectrum Methods 0.000 claims description 11
- 102000010792 Chromogranin A Human genes 0.000 claims description 9
- 108010038447 Chromogranin A Proteins 0.000 claims description 9
- 102000007469 Actins Human genes 0.000 claims description 7
- 108010085238 Actins Proteins 0.000 claims description 7
- 238000011088 calibration curve Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 238000012417 linear regression Methods 0.000 claims description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 208000035473 Communicable disease Diseases 0.000 abstract description 8
- 239000000090 biomarker Substances 0.000 abstract description 7
- 208000025721 COVID-19 Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 238000004458 analytical method Methods 0.000 description 32
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 28
- 108010061100 Nucleoproteins Proteins 0.000 description 27
- 241000700605 Viruses Species 0.000 description 27
- 238000012207 quantitative assay Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 102000011931 Nucleoproteins Human genes 0.000 description 26
- 238000003753 real-time PCR Methods 0.000 description 20
- 238000004949 mass spectrometry Methods 0.000 description 19
- 238000012205 qualitative assay Methods 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 14
- 235000019253 formic acid Nutrition 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000709661 Enterovirus Species 0.000 description 12
- 210000002345 respiratory system Anatomy 0.000 description 12
- 230000029087 digestion Effects 0.000 description 11
- 238000012544 monitoring process Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000006163 transport media Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 239000012491 analyte Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000342334 Human metapneumovirus Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000002553 single reaction monitoring Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 101710114810 Glycoprotein Proteins 0.000 description 3
- 241000711467 Human coronavirus 229E Species 0.000 description 3
- 241000482741 Human coronavirus NL63 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 101710167605 Spike glycoprotein Proteins 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 238000012113 quantitative test Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241001109669 Human coronavirus HKU1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000009709 capacitor discharge sintering Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000010460 detection of virus Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000037801 influenza A (H1N1) Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- QHGVXILFMXYDRS-UHFFFAOYSA-N pyraclofos Chemical compound C1=C(OP(=O)(OCC)SCCC)C=NN1C1=CC=C(Cl)C=C1 QHGVXILFMXYDRS-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 101710188691 Non-structural protein 7b Proteins 0.000 description 1
- 101710144120 Non-structural protein 8 Proteins 0.000 description 1
- 101710193592 ORF3a protein Proteins 0.000 description 1
- 101710082648 ORF9b protein Proteins 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 101710189624 Protein 7a Proteins 0.000 description 1
- 101710188658 Protein 9b Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101710193546 Tegument protein VP16 homolog Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 101710119834 Uncharacterized protein 14 Proteins 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021009475-3A BR102021009475B1 (pt) | 2021-05-14 | 2021-05-14 | Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021009475-3A BR102021009475B1 (pt) | 2021-05-14 | 2021-05-14 | Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR102021009475A2 BR102021009475A2 (enrdf_load_stackoverflow) | 2021-10-26 |
| BR102021009475B1 true BR102021009475B1 (pt) | 2022-09-20 |
Family
ID=83853055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102021009475-3A BR102021009475B1 (pt) | 2021-05-14 | 2021-05-14 | Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR102021009475B1 (enrdf_load_stackoverflow) |
-
2021
- 2021-05-14 BR BR102021009475-3A patent/BR102021009475B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR102021009475A2 (enrdf_load_stackoverflow) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cardozo et al. | Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts | |
| Messner et al. | Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection | |
| Bereman et al. | The development of selected reaction monitoring methods for targeted proteomics via empirical refinement | |
| Na et al. | Discovery of noncanonical translation initiation sites through mass spectrometric analysis of protein N termini | |
| Singh et al. | A rapid and sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry | |
| Van Puyvelde et al. | Cov-MS: a community-based template assay for mass-spectrometry-based protein detection in SARS-CoV-2 patients | |
| Griffin et al. | Mass spectrometry analytical responses to the SARS-CoV2 coronavirus in review | |
| Ceglarek et al. | Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC‐MS/MS | |
| Cardozo et al. | Fast and low-cost detection of SARS-CoV-2 peptides by tandem mass spectrometry in clinical samples | |
| JP2006317468A (ja) | 迅速かつ定量的なプロテオーム解析および関連した方法 | |
| Hober et al. | Rapid and sensitive detection of SARS-CoV-2 infection using quantitative peptide enrichment LC-MS analysis | |
| Lehmann et al. | Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold? | |
| BR112019025095A2 (pt) | Métodos para a quantificação absoluta de polipeptídeos de baixa abundância utilizando espectrometria de massa | |
| Bezstarosti et al. | Targeted proteomics for the detection of SARS-CoV-2 proteins | |
| Kontostathi et al. | Development and validation of multiple reaction monitoring (MRM) assays for clinical applications | |
| JP2022123057A (ja) | Ａｄａｍｔｓ１３酵素活性を決定するための方法およびシステム | |
| Beardsley et al. | Peptide de novo sequencing facilitated by a dual-labeling strategy | |
| Renuse et al. | Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens | |
| Svecla et al. | DDASSQ: An open‐source, multiple peptide sequencing strategy for label free quantification based on an OpenMS pipeline in the KNIME analytics platform | |
| Guo et al. | A qualitative and quantitative evaluation of the peptide characteristics of microwave‐and ultrasound‐assisted digestion in discovery and targeted proteomic analyses | |
| May et al. | Detecting modifications in proteomics experiments with Param-Medic | |
| Feng et al. | Selected reaction monitoring to measure proteins of interest in complex samples: a practical guide | |
| Li et al. | Analysis of urinary methylated nucleosides of patients with coronary artery disease by high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry | |
| Matthiesen et al. | Analysis of mass spectrometry data in proteomics | |
| BR102021009475B1 (pt) | Métodos para análise quantitativa e/ou qualitativa de marcadores peptídicos de sarscov-2 e usos de peptídeos de sars-cov-2 para fins de diagnóstico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2021, OBSERVADAS AS CONDICOES LEGAIS |